Key terms
About ACET
Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ACET news
Apr 22
4:42pm ET
Adicet Bio Showcases Promising ADI-270 Cancer Therapy Data
Apr 22
4:35pm ET
Adicet Bio’s new preclinical data highlighting ADI-270 selected for ASGCT
Apr 02
6:30am ET
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Mar 21
9:05am ET
Adicet Bio (ACET) Receives a New Rating from Truist Financial
Mar 20
12:26pm ET
Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials
Mar 20
10:55am ET
Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing
Mar 20
7:25am ET
Adicet Bio’s Promising Drug Pipeline and Buy Rating Justification
Mar 20
5:56am ET
Buy Recommendation for Adicet Bio Amid Promising Autoimmune and Cancer Therapy Developments
Mar 20
12:25am ET
JMP Securities Keeps Their Hold Rating on Adicet Bio (ACET)
Mar 19
4:13pm ET
Adicet Bio reports Q4 EPS (69c), consensus (69c)
Feb 13
2:02pm ET
Adicet upgraded to Buy on cell therapy potential at JonesResearch
Feb 13
1:56pm ET
Adicet Bio upgraded to Buy from Hold at JonesResearch
Feb 02
9:34am ET
Adicet Bio price target lowered to $10 from $26 at H.C. Wainwright
Jan 25
4:36am ET
Adicet Bio Announces Offering Pricing and Cash Position
Jan 25
4:36am ET
Adicet Bio Launches Public Stock and Warrant Offering
No recent press releases are available for ACET
ACET Financials
Key terms
Ad Feedback
ACET Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ACET Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range